Source:http://linkedlifedata.com/resource/pubmed/id/11220734
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2001-2-23
|
pubmed:abstractText |
We have defined a new paraneoplastic immunoglobulin G (IgG) autoantibody specific for CRMP-5, a previously unknown 62-kd neuronal cytoplasmic protein of the collapsin response-mediator family. CRMP-5 is in adult central and peripheral neurons, including synapses, and in small-cell lung carcinomas. Since 1993, our Clinical Neuroimmunology Laboratory has detected CRMP-5-IgG in 121 patients among approximately 68,000 whose sera were submitted for standardized immunofluorescence screening because a subacute neurological presentation was suspected to be paraneoplastic. This makes CRMP-5 autoantibody as frequent as PCA-1 (anti-Yo) autoantibody, second only to ANNA-1 (anti-Hu). Clinical information, obtained for 116 patients, revealed multifocal neurological signs. Most remarkable were the high frequencies of chorea (11%) and cranial neuropathy (17%, including 10% loss of olfaction/taste, 7% optic neuropathy). Other common signs were peripheral neuropathy (47%), autonomic neuropathy (31%), cerebellar ataxia (26%), subacute dementia (25%), and neuromuscular junction disorders (12%). Spinal fluid was inflammatory in 86%, and CRMP-5-IgG in 37% equaled or significantly exceeded serum titers. Lung carcinoma (mostly limited small-cell) was found in 77% of patients; thymoma was in 6%. Half of those remaining had miscellaneous neoplasms; all but two were smokers. Serum IgG in all cases bound to recombinant CRMP-5 (predominantly N-terminal epitopes), but not to human CRMP-2 or CRMP-3.
|
pubmed:grant | |
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0364-5134
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
49
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
146-54
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11220734-Amino Acid Sequence,
pubmed-meshheading:11220734-Autoimmunity,
pubmed-meshheading:11220734-Base Sequence,
pubmed-meshheading:11220734-Humans,
pubmed-meshheading:11220734-Lung Neoplasms,
pubmed-meshheading:11220734-Molecular Sequence Data,
pubmed-meshheading:11220734-Nerve Tissue Proteins,
pubmed-meshheading:11220734-Thymoma,
pubmed-meshheading:11220734-Thymus Neoplasms,
pubmed-meshheading:11220734-Tumor Markers, Biological
|
pubmed:year |
2001
|
pubmed:articleTitle |
CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.
|
pubmed:affiliation |
Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|